Allergan plans to develop novel treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases through the acquisition of Akarna Therapeutics. The acquisition has been completed for a purchase consideration of $50m.
Pursuant to the acquisition, Allergan will gain all rights to AKN-083 and a portfolio of additional development stage FXR compounds. Akarna Therapeutics will receive additional clinical, regulatory, developmental and commercialisation milestones of its drug candidate.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Walvax Biotechnology, a bio-pharmaceutical vaccination product provider, has announced to sell 85% shares in Shandong Shijie Biological Technology.
Walvax Biotechnology expects to receive gross proceeds of up to $104.5m from the transaction.
